The Latest Breaking News from AbbVie

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Benzinga · Nov 26, 2024

Market Whales and Their Recent Bets on ABBV Options

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Benzinga · Nov 25, 2024

3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

Barchart · Nov 16, 2024

Are Wall Street Analysts Bullish on AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart · Nov 7, 2024

Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

Barchart · Oct 30, 2024

HR leaders share how they're putting people first in an ever-changing workplace

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

Fortune · Oct 21, 2024

3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

Barchart · Oct 18, 2024

AbbVie's Q3 2024 Earnings: What to Expect

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

Barchart · Oct 14, 2024

3 Highest-yielding Dividend Kings for Maximum Income and Stability

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Barchart · Oct 11, 2024

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation · Oct 2, 2024